Docsity
Docsity

Prepare for your exams
Prepare for your exams

Study with the several resources on Docsity


Earn points to download
Earn points to download

Earn points by helping other students or get them with a premium plan


Guidelines and tips
Guidelines and tips

Impact of BiVentricular Pacing on Heart Failure Patients, Slides of Medicine

Information on cardiac resynchronization therapy (crt), specifically biventricular pacing, and its effects on heart failure patients. Details from various studies such as miracle icd and companion, which examine the benefits of crt in reducing the risk of death and hospitalization. The care hf study is also discussed, which focuses on the effect of crt on mortality and morbidity in patients with heart failure and dysynchrony. The document concludes with the latest crt guidelines.

Typology: Slides

2011/2012

Uploaded on 12/13/2012

sethuraman_h34rt
sethuraman_h34rt 🇮🇳

4.3

(8)

159 documents

1 / 16

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
Cardiac Resynchronization
Therapy
BiVentricular Pacing
Docsity.com
pf3
pf4
pf5
pf8
pf9
pfa
pfd
pfe
pff

Partial preview of the text

Download Impact of BiVentricular Pacing on Heart Failure Patients and more Slides Medicine in PDF only on Docsity!

Cardiac Resynchronization

Therapy

BiVentricular Pacing

Cardiac Dysynchrony

►Some Heart failure patients will suffer from

dysynchrony. It is thought that this

dysynchrony can further impair their overall

cardiac function. IF the ventricles beat

together, the thought is that there will be

less regional loading disparities.

►As upgraded, ICD’s, with coronary sinus

leads have the capability of pacing both

ventricles, we should see which patients

benefit from BiV pacing.

MIRACLE ICD

► Multicenter InSync

Randomized Clinical

Evaluation

► JAMA 2003

► Small study, using a

survey to look at

symptoms.

► Not powered to detect

a mortality difference.

MIRACLE ICD

COMPANION

►1527 patients

 NYHA III or IV (ischemic or nonischemic)

 QRS >

►Assigned to one of three groups

 Pharamcologic therapy alone

 Above + CRT

 Above + CRT + ICD

►Primary endpoint: composite of death or

hospitalization for any cause.

Companion Results

► After 12 months

 68% composite end point in pharacological group.

 56% in BIV alone

 56% in ICD + BIV group.

► Secondary endpoint (death from any cause)

 Pharmacological 19%

 BIV (hazard ration of .76, CI of .58 to 1.01, p 0.059) –

near significant

 BIV ICD: 36% reduction, Hazard ratio .64, CI .48 to .86,

P0.

CARE HF

► CArdiac REsynchronization in Heart Failure

Study

► Looked at the effect on mortality and

morbitity by CRT in patients with evidence of

dysyncrhony and heart failure. THIS STUDY

IS WITHOUT DEFIBRILLATORS.

NYHA Class III or IV

LVEF < 35%

QRS > 150, or 120 w/ other signs of dyssynchrony

by echo.

► NEJM: 2005

CARE HF

  • Not a blinded study.
  • Primary end point was MACE
  • Secondary endpoint all casue mortality
  • @ 28 months
    • Reduction in MACE in 39 vs 55%
    • This benefit does increase over time
    • Also a reduction in overall mortaliyt of

20% vs 30%. Biggest finding is that

this drop was found to mostly be in less

deaths from worsening heart failure.

Shows the benefits of Bi Ventricular pacing

and CRT alone in survival in HF.

CARE HF Hemodynamic, Echocardiographic, and Biochemical Assessments

Cleland, J. et al. N Engl J Med 2005;352:1539-

CRT guideline

► Class I Recommendation for CRT Therapy

► “Patients with LVEF less than or equal to 35%,

sinus rhythm, and NYHA functional class III or

ambulatory class IV symptoms despite

recommended, optimal medical therapy and who

have cardiac dyssynchrony, which is currently

defined as a QRS duration greater than 120 ms,

should receive cardiac resynchronization therapy

unless contraindicated.” (Level of Evidence: A)

Cardiac Resynchronization Therapy*

in Patients With Severe Systolic

Heart Failure

For patients with LVEF less than or equal to 35% with
NYHA functional Class I or II symptoms who are receiving
optimal recommended medical therapy and who are
undergoing implantation of a permanent pacemaker
and/or ICD with anticipated frequent ventricular pacing,
CRT may be considered.
CRT is not indicated for asymptomatic patients with
reduced LVEF in the absence of other indications for
pacing.
CRT is not indicated for patients whose functional status
and life expectancy are limited predominantly by chronic
noncardiac conditions.

I

I

I

IIa

IIa

IIa

IIb

IIb

IIb

III

III

III

I

I

I

IIa

IIa

IIa

IIb

IIb

IIb

III

III

III

I

I

I

IIa

IIa

IIa

IIb

IIb

IIb

III

III

III

IIa

IIa

IIa

IIb

IIb

IIb

III

III

III

I

I

I

IIa

IIaIIa IIb

IIbIIb III

IIIIII I

I

I

IIa

IIaIIa IIb

IIbIIb III

IIIIII I

I

I

IIa

IIaIIa IIb

IIbIIb III

IIIIII IIa

IIaIIa IIb

IIbIIb III

IIIIII

I

I

I

IIa

IIaIIa IIb

IIbIIb III

IIIIII I

I

I

IIa

IIaIIa IIb

IIbIIb III

IIIIII I

I

I

IIa

IIaIIa IIb

IIbIIb III

IIIIII IIa

IIaIIa IIb

IIbIIb III

IIIIII

*All primary SCD prevention ICD recommendations apply only to patients who are receiving optimal medical therapy and have reasonable expectation

of survival with good functional capacity for more than 1 year.